These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 17702632

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Myths and realities of continuous dopaminergic stimulation.
    Pirtošek Z.
    Psychiatr Danub; 2011 Mar; 23(1):80-3. PubMed ID: 21448103
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.
    Di Rosa AE, Epifanio A, Antonini A, Stocchi F, Martino G, Di Blasi L, Tetto A, Basile G, Imbesi D, La Spina P, Di Raimondo G, Morgante L.
    Neurol Sci; 2003 Oct; 24(3):174-5. PubMed ID: 14598073
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D, Constantinescu R, Holmberg B, Dizdar N, Askmark H.
    Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
    [Abstract] [Full Text] [Related]

  • 12. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
    Stacy M, Galbreath A.
    Clin Neuropharmacol; 2008 May; 31(1):51-6. PubMed ID: 18303491
    [Abstract] [Full Text] [Related]

  • 13. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A, Devos D, Seguy D, Dujardin K, Destée A, Defebvre L.
    Rev Neurol (Paris); 2009 May; 165(8-9):718-27. PubMed ID: 19150100
    [Abstract] [Full Text] [Related]

  • 14. Influence of subthalamic deep brain stimulation versus levodopa on motor perseverations in Parkinson's disease.
    Herzog J, Möller B, Witt K, Pinsker MO, Deuschl G, Volkmann J.
    Mov Disord; 2009 Jun 15; 24(8):1206-10. PubMed ID: 19412937
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prognostic factors of subthalamic stimulation in Parkinson's disease: a comparative study between short- and long-term effects.
    Tsai ST, Lin SH, Chou YC, Pan YH, Hung HY, Li CW, Lin SZ, Chen SY.
    Stereotact Funct Neurosurg; 2009 Jun 15; 87(4):241-8. PubMed ID: 19556833
    [Abstract] [Full Text] [Related]

  • 17. Deep brain stimulation and its effect on sleep in Parkinson's disease.
    Antonini A, Landi A, Mariani C, DeNotaris R, Pezzoli G.
    Sleep Med; 2004 Mar 15; 5(2):211-4. PubMed ID: 15033146
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease.
    Sage JI, Mark MH.
    Neurology; 1992 Jan 15; 42(1 Suppl 1):23-8; discussion 57-60. PubMed ID: 1347908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.